

## DISCLOSURE OF RELEVANT RELATIONSHIPS & CONFIDENTIALITY STATEMENTS

For NIA-AA Guidelines Workgroup

*Confidential*

### **DISCLOSURE OF RELEVANT RELATIONSHIPS**

For each of the categories below, (1) please disclose relationships that cover the last 12 months and for anticipated activities in the coming 12 months as of approximately April 2016. If you have none, please write "none." Relationships apply to you and to spouse or dependent children. (2) For each relationship, please indicate whether it is a "**Significant ( $\geq$ \$1,000) Financial Interest**" Financial interests include but are not limited to salary, consulting and / or speaker fees, honoraria, research support, equity interests (e.g., stocks, stock options, or other ownership interests), and intellectual property rights (e.g., patents, copyrights and royalties from such rights).

1. Research funding (federal, foundation and corporate) relevant to the topic of Alzheimer's disease.

I receive research funding from the European IMI, H2020 program and the Spanish ISCIII

2. Consulting to a for-profit company (paid and unpaid) relevant to the topic of Alzheimer's disease.

Roche	_____	Consultant, speaker
Roche diagnostics	_____	Consultant
Axovant	_____	Consultant
Lundbeck	_____	Consultant, speaker
General Electric	_____	Consultant
IBL	_____	Consultant
Lilly	_____	Consultant, speaker
Novartis		Consultant, speaker
Otsuka		Consultant
Oryzon		Consultant
MSD		Consultant

All of them relevant

3. Ownership of property relevant to the topic of Alzheimer's disease (patents filed or approved, licenses and other property shares) -- for each, please indicate whether you do or do not accept royalties.

None

4. Equity in companies whose work is relevant to the topic of Alzheimer's disease

None

5. Employment in companies whose work is relevant to the topic of Alzheimer's disease

None

6. Relevant scientific work to the NIA-AA Workgroup discussions.

A relevant proportion of both my clinical and research work is related with the proper use of CSF biomarkers. Among other things, I have personally worked on developing preanalytical and analytical

SOPs, defining cut offs, conducting prospective studies on the value of CSF biomarkers and creating guidelines and recommendations for the use of CSF biomarkers.

I will immediately notify NIA-AA Workgroup leads if a change occurs in any of the above during the tenure of my responsibilities,



José Luis Molinuevo \_\_\_\_\_  
Name

Signature

\_\_\_\_\_ August 21, 2017

Date